149 related articles for article (PubMed ID: 29683977)
1. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1.
Sato Y; Ueno H; Ioka T; Ohkawa S; Ikeda M; Shimamura T; Tsuji A; Tsuchiya Y; Furuse J; Ishii H; Furuya K; Iguchi H; Saito Y; Kaniwa N; Sawada JI; Sakamoto H; Sekine A; Okusaka T; Yoshida T;
Pancreas; 2018; 47(5):637-642. PubMed ID: 29683977
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
Imaoka H; Kou T; Tanaka M; Egawa S; Mizuno N; Hijioka S; Hara K; Yazumi S; Shimizu Y; Yamao K
Eur J Cancer; 2016 Feb; 54():96-103. PubMed ID: 26741729
[TBL] [Abstract][Full Text] [Related]
3. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
[TBL] [Abstract][Full Text] [Related]
4. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Okusaka T; Miyakawa H; Fujii H; Nakamori S; Satoh T; Hamamoto Y; Ito T; Maguchi H; Matsumoto S; Ueno H; Ioka T; Boku N; Egawa S; Hatori T; Furuse J; Mizumoto K; Ohkawa S; Yamaguchi T; Yamao K; Funakoshi A; Chen JS; Cheng AL; Sato A; Ohashi Y; Tanaka M;
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1053-1059. PubMed ID: 28210843
[TBL] [Abstract][Full Text] [Related]
5. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
[TBL] [Abstract][Full Text] [Related]
7. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
Imaoka H; Ikeda M; Maehara K; Umemoto K; Ozaka M; Kobayashi S; Terashima T; Inoue H; Sakaguchi C; Tsuji K; Shioji K; Okamura K; Kawamoto Y; Suzuki R; Shirakawa H; Nagano H; Ueno M; Morizane C; Furuse J
BMC Cancer; 2020 Oct; 20(1):946. PubMed ID: 33004032
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus S-1 for metastatic pancreatic cancer.
Zhu H; Yi C; Zhao Y; Gou H
Medicine (Baltimore); 2018 Oct; 97(41):e12836. PubMed ID: 30313120
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Ueno M; Okusaka T; Omuro Y; Isayama H; Fukutomi A; Ikeda M; Mizuno N; Fukuzawa K; Furukawa M; Iguchi H; Sugimori K; Furuse J; Shimada K; Ioka T; Nakamori S; Baba H; Komatsu Y; Takeuchi M; Hyodo I; Boku N
Ann Oncol; 2016 Mar; 27(3):502-8. PubMed ID: 26681680
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Ueno H; Ioka T; Ikeda M; Ohkawa S; Yanagimoto H; Boku N; Fukutomi A; Sugimori K; Baba H; Yamao K; Shimamura T; Sho M; Kitano M; Cheng AL; Mizumoto K; Chen JS; Furuse J; Funakoshi A; Hatori T; Yamaguchi T; Egawa S; Sato A; Ohashi Y; Okusaka T; Tanaka M
J Clin Oncol; 2013 May; 31(13):1640-8. PubMed ID: 23547081
[TBL] [Abstract][Full Text] [Related]
14. [A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy].
Kuji M; Yamamoto Y; Tani C; Kenno S; Kobayashi T
Gan To Kagaku Ryoho; 2011 May; 38(5):853-5. PubMed ID: 21566453
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
Xu Y; Guo X; Fan Y; Wang D; Wu W; Wu L; Liu T; Xu B; Feng Y; Wang Y; Lou W; Zhou Y
Jpn J Clin Oncol; 2018 Jun; 48(6):535-541. PubMed ID: 29718363
[TBL] [Abstract][Full Text] [Related]
16. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer.
Iede K; Yamada T; Kato R; Ueda M; Tsuda Y; Nakashima S; Ohta K; Matsuyama J; Ikenaga M; Tominaga S
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1215. PubMed ID: 32672000
[TBL] [Abstract][Full Text] [Related]
18. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
Huang PW; Chang CF; Hung CY; Hsueh SW; Chang PH; Yeh KY; Chen JS; Chen YY; Lu CH; Hung YS; Chou WC
Cancer Med; 2019 Sep; 8(12):5554-5563. PubMed ID: 31385456
[TBL] [Abstract][Full Text] [Related]
19. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.
Xue P; Zhu L; Wan Z; Huang W; Li N; Chen D; Hu J; Yang H; Wang L
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1653-60. PubMed ID: 25792009
[TBL] [Abstract][Full Text] [Related]
20. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Ioka T; Komatsu Y; Mizuno N; Tsuji A; Ohkawa S; Tanaka M; Iguchi H; Ishiguro A; Kitano M; Satoh T; Yamaguchi T; Takeda K; Kida M; Eguchi K; Ito T; Munakata M; Itoi T; Furuse J; Hamada C; Sakata Y
Br J Cancer; 2017 Feb; 116(4):464-471. PubMed ID: 28081543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
